• Graduate Programs
  • Research
  • Browse our Courses
  • Events
    • Events Calendar
    • Events Archive
    • Summer School
      • Applied Public Policy Evaluation
      • Deep Learning
      • Development Economics
      • Economics of Blockchain and Digital Currencies
      • Economics of Climate Change
      • The Economics of Crime
      • Foundations of Machine Learning with Applications in Python
      • From Preference to Choice: The Economic Theory of Decision-Making
      • Inequalities in Health and Healthcare
      • Marketing Research with Purpose
      • Markets with Frictions
      • Modern Toolbox for Spatial and Functional Data
      • Sustainable Finance
      • Tuition Fees and Payment
      • Business Data Science Summer School Program
    • Tinbergen Institute Lectures
    • 2026 Tinbergen Institute Opening Conference
    • Annual Tinbergen Institute Conference
  • News
  • Summer School
    • Applied Public Policy Evaluation
    • Deep Learning
    • Development Economics
    • Economics of Blockchain and Digital Currencies
    • Economics of Climate Change
    • The Economics of Crime
    • Foundations of Machine Learning with Applications in Python
    • From Preference to Choice: The Economic Theory of Decision-Making
    • Inequalities in Health and Healthcare
    • Marketing Research with Purpose
    • Markets with Frictions
    • Modern Toolbox for Spatial and Functional Data
    • Sustainable Finance
    • Tuition Fees and Payment
  • Alumni

Kamphorst, J. and Karamychev, V. (2025). Going through the roof: On prices for drugs sold through insurance Games and Economic Behavior, 151:218--242.


  • Journal
    Games and Economic Behavior

This paper studies public concern grounds for high prices of drugs treating rare and debilitating diseases. We offer a theory that explains how drug indivisibility, individual budget constraints, and insurance interact to drive up drug prices, especially for drugs treating rare and severe diseases. For a broad range of drug production costs and income distributions, our model predicts that drug prices are either set at their highest levels covered by insurance or inversely related to the prevalence of the disease. In the latter case, producer profits decrease with prevalence. The effect of production costs on prices and profits is non-monotonic.